Copyright Reports & Markets. All rights reserved.

Global Taletrectinib Adipate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Taletrectinib Adipate Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 33 capsules / bottle
    • 1.3.3 30 capsules / bottle
  • 1.4 Market Analysis by Indicated Population
    • 1.4.1 Overview: Global Taletrectinib Adipate Consumption Value by Indicated Population: 2021 Versus 2025 Versus 2032
    • 1.4.2 ROS1 Fusion Gene-Positive Adult Patients with Advanced or Metastatic Non-Small Cell Lung Cancer**
    • 1.4.3 NTRK Fusion Gene-Positive Patients with Advanced Solid Tumors**
  • 1.5 Market Analysis by Sales Channels
    • 1.5.1 Overview: Global Taletrectinib Adipate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospitals
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Production Technology
    • 1.6.1 Overview: Global Taletrectinib Adipate Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.6.2 Original
    • 1.6.3 Generic
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Taletrectinib Adipate Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Ros1 Fusion-Positive Locally Advanced
    • 1.7.3 Metastatic Non-Small Cell Lung Cancer (NSCLC)
    • 1.7.4 Others
  • 1.8 Global Taletrectinib Adipate Market Size & Forecast
    • 1.8.1 Global Taletrectinib Adipate Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Taletrectinib Adipate Sales Quantity (2021-2032)
    • 1.8.3 Global Taletrectinib Adipate Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 AnHeart Therapeutics
    • 2.1.1 AnHeart Therapeutics Details
    • 2.1.2 AnHeart Therapeutics Major Business
    • 2.1.3 AnHeart Therapeutics Taletrectinib Adipate Product and Services
    • 2.1.4 AnHeart Therapeutics Taletrectinib Adipate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 AnHeart Therapeutics Recent Developments/Updates
  • 2.2 Innovent Biologics
    • 2.2.1 Innovent Biologics Details
    • 2.2.2 Innovent Biologics Major Business
    • 2.2.3 Innovent Biologics Taletrectinib Adipate Product and Services
    • 2.2.4 Innovent Biologics Taletrectinib Adipate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Innovent Biologics Recent Developments/Updates
  • 2.3 Asymchem Life Sciences Tianjin) C
    • 2.3.1 Asymchem Life Sciences Tianjin) C Details
    • 2.3.2 Asymchem Life Sciences Tianjin) C Major Business
    • 2.3.3 Asymchem Life Sciences Tianjin) C Taletrectinib Adipate Product and Services
    • 2.3.4 Asymchem Life Sciences Tianjin) C Taletrectinib Adipate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Asymchem Life Sciences Tianjin) C Recent Developments/Updates
  • 2.4 Daiichi Sankyo
    • 2.4.1 Daiichi Sankyo Details
    • 2.4.2 Daiichi Sankyo Major Business
    • 2.4.3 Daiichi Sankyo Taletrectinib Adipate Product and Services
    • 2.4.4 Daiichi Sankyo Taletrectinib Adipate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Daiichi Sankyo Recent Developments/Updates

3 Competitive Environment: Taletrectinib Adipate by Manufacturer

  • 3.1 Global Taletrectinib Adipate Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Taletrectinib Adipate Revenue by Manufacturer (2021-2026)
  • 3.3 Global Taletrectinib Adipate Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Taletrectinib Adipate by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Taletrectinib Adipate Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Taletrectinib Adipate Manufacturer Market Share in 2025
  • 3.5 Taletrectinib Adipate Market: Overall Company Footprint Analysis
    • 3.5.1 Taletrectinib Adipate Market: Region Footprint
    • 3.5.2 Taletrectinib Adipate Market: Company Product Type Footprint
    • 3.5.3 Taletrectinib Adipate Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Taletrectinib Adipate Market Size by Region
    • 4.1.1 Global Taletrectinib Adipate Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Taletrectinib Adipate Consumption Value by Region (2021-2032)
    • 4.1.3 Global Taletrectinib Adipate Average Price by Region (2021-2032)
  • 4.2 North America Taletrectinib Adipate Consumption Value (2021-2032)
  • 4.3 Europe Taletrectinib Adipate Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Taletrectinib Adipate Consumption Value (2021-2032)
  • 4.5 South America Taletrectinib Adipate Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Taletrectinib Adipate Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Taletrectinib Adipate Sales Quantity by Type (2021-2032)
  • 5.2 Global Taletrectinib Adipate Consumption Value by Type (2021-2032)
  • 5.3 Global Taletrectinib Adipate Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Taletrectinib Adipate Sales Quantity by Application (2021-2032)
  • 6.2 Global Taletrectinib Adipate Consumption Value by Application (2021-2032)
  • 6.3 Global Taletrectinib Adipate Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Taletrectinib Adipate Sales Quantity by Type (2021-2032)
  • 7.2 North America Taletrectinib Adipate Sales Quantity by Application (2021-2032)
  • 7.3 North America Taletrectinib Adipate Market Size by Country
    • 7.3.1 North America Taletrectinib Adipate Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Taletrectinib Adipate Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Taletrectinib Adipate Sales Quantity by Type (2021-2032)
  • 8.2 Europe Taletrectinib Adipate Sales Quantity by Application (2021-2032)
  • 8.3 Europe Taletrectinib Adipate Market Size by Country
    • 8.3.1 Europe Taletrectinib Adipate Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Taletrectinib Adipate Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Taletrectinib Adipate Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Taletrectinib Adipate Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Taletrectinib Adipate Market Size by Region
    • 9.3.1 Asia-Pacific Taletrectinib Adipate Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Taletrectinib Adipate Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Taletrectinib Adipate Sales Quantity by Type (2021-2032)
  • 10.2 South America Taletrectinib Adipate Sales Quantity by Application (2021-2032)
  • 10.3 South America Taletrectinib Adipate Market Size by Country
    • 10.3.1 South America Taletrectinib Adipate Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Taletrectinib Adipate Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Taletrectinib Adipate Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Taletrectinib Adipate Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Taletrectinib Adipate Market Size by Country
    • 11.3.1 Middle East & Africa Taletrectinib Adipate Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Taletrectinib Adipate Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Taletrectinib Adipate Market Drivers
  • 12.2 Taletrectinib Adipate Market Restraints
  • 12.3 Taletrectinib Adipate Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Taletrectinib Adipate and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Taletrectinib Adipate
  • 13.3 Taletrectinib Adipate Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Taletrectinib Adipate Typical Distributors
  • 14.3 Taletrectinib Adipate Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Taletrectinib Adipate market size was valued at US$ 46.30 million in 2025 and is forecast to a readjusted size of US$ 436 million by 2032 with a CAGR of 25.2% during review period.
    Taletrectinib Adipate is an oral, highly selective small‑molecule tyrosine kinase inhibitor and a new generation of antineoplastic agent targeting ROS1 and NTRK fusion genes. It exerts potent antitumor activity by selectively inhibiting ROS1 and NTRK kinase activities, blocking downstream signaling pathways involved in tumor cell proliferation, differentiation and metastasis. It demonstrates significant inhibitory activity against crizotinib‑resistant mutations such as ROS1 G2032R. It is mainly indicated for the treatment of ROS1‑positive advanced or metastatic non‑small cell lung cancer and NTRK fusion‑positive solid tumors, characterized by strong antitumor activity, excellent central nervous system penetration and broad coverage of resistant mutationsIn 2025, global taletrectinib adipate (己二酸他雷替尼，brand name Ibtrozi) production reached approximately 120,000–150,000 bottles
    Taletrectinib adipate demonstrates significant market competitiveness in the global treatment of ROS1 and NTRK fusion-positive tumors owing to its excellent target selectivity, potent intracranial antitumor activity, and favorable control over drug-resistant mutations. With the popularization of precision medicine and genetic testing, the clinical demand for such targeted drugs continues to rise. By virtue of its superior efficacy and safety compared with first-generation products, taletrectinib adipate has gradually become an important option for the treatment of advanced non-small cell lung cancer and solid tumors. Driven by policy support at home and abroad, the advancement of medical insurance access, and global commercialization layout, its market coverage has been continuously expanded and patient accessibility steadily improved. The overall market shows a steady growth trend, with broad application prospects and promising market potential in both first-line and post-resistance treatment settings.
    This report is a detailed and comprehensive analysis for global Taletrectinib Adipate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Taletrectinib Adipate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Taletrectinib Adipate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Taletrectinib Adipate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Taletrectinib Adipate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Taletrectinib Adipate
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Taletrectinib Adipate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AnHeart Therapeutics, Innovent Biologics, Asymchem Life Sciences Tianjin) C, Daiichi Sankyo, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Taletrectinib Adipate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    33 capsules / bottle
    30 capsules / bottle
    Market segment by Indicated Population
    ROS1 Fusion Gene-Positive Adult Patients with Advanced or Metastatic Non-Small Cell Lung Cancer**
    NTRK Fusion Gene-Positive Patients with Advanced Solid Tumors**
    Market segment by Sales Channels
    Hospitals
    Retail
    Online
    Market segment by Production Technology
    Original
    Generic
    Market segment by Application
    Ros1 Fusion-Positive Locally Advanced
    Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Others
    Major players covered
    AnHeart Therapeutics
    Innovent Biologics
    Asymchem Life Sciences Tianjin) C
    Daiichi Sankyo
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Taletrectinib Adipate product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Taletrectinib Adipate, with price, sales quantity, revenue, and global market share of Taletrectinib Adipate from 2021 to 2026.
    Chapter 3, the Taletrectinib Adipate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Taletrectinib Adipate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Taletrectinib Adipate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Taletrectinib Adipate.
    Chapter 14 and 15, to describe Taletrectinib Adipate sales channel, distributors, customers, research findings and conclusion.

    Buy now